Biologic Medications for Psoriasis, HS, AD, PN, CSU, and BP
Brownstone-Lebwohl
Quick Reference Chart
This table is not intended to replace medical judgment.
Brand Name | Generic Name | Ages | Loading Dose | Maintenance Dose | Mechanism of Action |
|---|---|---|---|---|---|
| PSORIASIS | |||||
Enbrel* | Etanercept | PsA 18 yrs + | 50 mg SQ Twice Weekly for 12 wks | 50 mg SQ q wk | TNF-α blocker |
PEDS: 0.8 mg/kg q wk (max-dose 50 mg q wk) | |||||
Humira* | Adalimumab | PsO / PsA 18 yrs + | 80 mg SQ on Day 1 and then | 40 mg SQ q2 wks | TNF-α blocker |
Remicade* | lnfliximab | PsO / PsA 18 yrs + | 5 mg/kg IV wk 0, 2, and 6 | 5 mg/kg IV q8 wks | TNF-α blocker |
Cimzia* | Certolizumab Pegol | PsO / PsA 18 yrs + | >90 kg: No Loading Dose | 400 mg SQ q2 wks | TNF-α blocker |
≤90 kg: 400 mg SQ at wk 0, 2 and 4 | 200 mg SQ q2 wks | ||||
Bimzelx* | Bimekizumab | PsO / PsA 18 yrs + | 320 mg SQ at wk 0, 4, 8, 12, and 16 | 320 mg SQ q8 wks (for patients ≥ 120 kg, consider 320 mg q4 wks after wk 16) | IL-17A and F antagonist |
Cosentyx* | Secukinumab | PsA 2 yrs + | 300 mg SQ at wk 0, 1, 2, 3, and 4 | 300 mg SQ q4 wks | IL-17A antagonist |
PEDS: Dosage based on body weight and administered by SQ at wks 0, 1, 2, 3, and 4 and q4 wks | |||||
Taltz* | lxekizumab | PsA 18 yrs + | 160 mg at wk 0, then 80 mg at wk 2, 4, 6, 8, 10, and 12 | 80 mg SQ q4 wks | IL-17A antagonist |
PEDS: Greater than 50 kg = 160 mg at wk 0 then 80 mg q4 wks | 25 to 50 kg = 80 mg at wk 0 then 40 mg q4 wks | Less than 25 kg = 40 mg at wk 0 then 20 mg q4 wks | |||||
Siliq | Brodalumab | PsO 18 yrs + | 210 mg SQ at wk 0, 1, and 2 | 210 mg SQ q2 wks | IL-17A receptor antagonist |
Stelara* | Ustekinumab | PsA 6 yrs + | ≤l00 kg: 45 mg SQ at wk 0 and 4 | 45 mg SQ q12 wks | IL-12 and IL-23 antagonist |
>l00 kg: 90 mg SQ at wk 0 and 4 | 90 mg SQ q12 wks | ||||
PEDS: Weight-based dosing recommended at initial dose, 4 weeks later, then q12 weeks. | |||||
Tremfya* | Guselkumab | PsO / PsA 6 yrs + (weighing at least 40 kg) | 100 mg SQ at wk 0 and 4 | 100 mg SQ q8 wks | IL-23 antagonist |
llumya | Tildrakizumab | PsO 18 yrs + | 100 mg SQ at wk 0 and 4 | 100 mg SQ q12 wks | IL-23 antagonist |
Skyrizi* | Risankizumab | PsO / PsA 18 yrs + | 150 mg SQ at wk 0 and 4 | 150 mg SQ q12 wks | IL-23 antagonist |
Spevigo (GPP) | Spesolimab | 12 yrs + (weighing at least 40 kg) | For treatment of flare: 900 mg IV | For treatment of flare: Repeat in one week if flare persists | IL-36 receptor antagonist |
| HIDRADENITIS SUPPURATIVA | |||||
Humira | Adalimumab | 12 yrs + | Day 1: 160 mg (given in one day or split over 2 consecutive days); Day 15: 80 mg; Day 29: 40 mg q wk or 80 mg q2 wk | 40 mg q wk or 80 mg q2 wks | TNF-α blocker |
PEDS: 30 kg to <60 kg: Day 1: 80 mg; Day 8: 40 mg TNF-α blocker | PEDS: 30 kg to <60 kg: 40 mg q2 wks | ||||
Cosentyx | Secukinumab | 18 yrs + | 300 mg at wk 0, 1, 2, 3, and 4 | 300 mg q4 wks; if inadequate response 300 mg q2 wks may be considered | IL-17A antagonist |
Bimzelx | Bimekizumab | 18 yrs + | 320 mg at wk 0, 2, 4, 6, 8, 10, 12, 14, and 16 | 320 mg q4 wks | IL-17A and F antagonist |
| ATOPIC DERMATITIS | |||||
Dupixent | Dupilumab | 6 mos + | 600 mg SQ | 300 mg SQ q2 wk | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
PEDS 6m–5y: 5 to less than 15 kg = 200 mg SQ q4 wks | 15 to less than 30 kg = 300 mg SQ q4 wks PEDS 6y–17y: 15 to less than 30 kg = 600 mg SQ then 300 mg q4 wks | 30 to less than 60 kg = 400 mg SQ then 200 mg q2 wks | 60 kg + = 600 mg SQ then 300 mg q2 wks | |||||
Ebglyss | Lebrikizumab | 12 yrs + (weighing at least 40 kg) | 500 mg at wk 0 and 2, then 250 mg q2 wks until 16 wks or later, when adequate clinical response is achieved | 250 mg q4 wks | IL-13 antagonist |
Adbry | Tralokinumab | 12 yrs + | Adults: 600 mg | Adults: 300 mg q2 wks; after 16 wks, q4 wks may be considered for adults <220 lbs who achieve clear or almost clear skin | IL-13 antagonist |
PEDS 12y-17y: 300 mg | PEDS 12y-17y: 150 mg q2 wks | ||||
Nemluvio | Nemolizumab | 12 yrs + | 60 mg SQ | 30 mg SQ q4 wks; for patients achieving clear or almost clear skin at 16 wks, 30 mg q8 wks recommended. Use with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies | IL-31 receptor antagonist |
| PRURIGO NODULARIS | |||||
Dupixent | Dupilumab | 18 yrs + | 600 mg | 300 mg q2 wks | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
Nemluvio | Nemolizumab | 18 yrs + | Adults weighing ≥90 kg: 60 mg | Adults weighing ≥90 kg: 60 mg q4 wks | IL-31 receptor antagonist |
| CHRONIC SPONTANEOUS URTICARIA | |||||
Xolair | Omalizumab | 12 yrs + | None | 150 mg or 300 mg q4 wks | anti-IgE antibody |
Dupixent | Dupilumab | 12 yrs + | 600 mg | 300 mg q2 wks | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
PEDS: 30 to <60 kg = 400 mg | 60 kg or more = 600 mg | PEDS: 30 to <60 kg = 200 mg q2 wks | 60 kg or more = 300 mg q2 wks | ||||
| BULLOUS PEMPHIGOID | |||||
Dupixent | Dupilumab | 18 yrs + | 600 mg | 300 mg q2 wks; use in combination with tapering course of oral corticosteroids | IL-4 receptor-α antagonist (inhibits IL-4 and IL-13) |
SQ = subcutaneous, q = every, wk/W = weeks,
PsO = psoriasis, PsA = psoriatic arthritis, PEDS = pediatric dosing,
GPP = generalized pustular psoriasis
PN = prurigo nodularis
CSU=chronic spontaneous urticaria
BP = bullous pemphigoid
*FDA approved to treat both psoriasis and psoriatic arthritis.
DISCLAIMER: The dosages seen in this chart were obtained from the respective FDA approved package inserts for psoriasis, hidradenitis suppurativa, atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. This chart is for reference only and not to be substituted for clinical judgment. The authors are not responsible for treatment decisions or outcomes based on the information in this chart.
v9 - October 2025 – Copyright 2025 Mark Lebwohl, MD and Nicholas Brownstone, MD.